Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Oncotelic Therapeutics Inc (QB)
OTLC
Healthcare
Biotechnology
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2,...
which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson’s disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support techno...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (OTCQB:OTLC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Mar 10, 2022 2:15pm
Oncotelic to Present New Studies on its TGF-ß Program at the
Oncotelic to Present New Studies on its TGF- Program at the American Association for Cancer Research (AACR) Annual Meeting 2022: https://apnews.com/press-release/globe-newswire/covid-science
...more
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Mar 02, 2022 5:56pm
Oncotelic; An Introduction to CFO Amit Shah & His Industry B
https://www.youtube.com/watch?v=D4k5OEUYvbk
Blue Sky Uranium Advances Ivana Project with Metallurgical Test Program
posted May 12, 2026 9:00am by
Blue Sky Uranium Corp.
-
|
The Company announced that its joint venture operating company Ivana Minerales S.A. has executed service agreements with M3 Engineering & Technology and the Saskatchewan Research Council to support engineering and metallurgical testing programs for the Ivana Uranium-Vanadium Project in Argentina ...read more
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Jan 05, 2022 11:36am
Oncotelic Initiates Phase 1 Trial Evaluating CA4P...
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma (yahoo.com)
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Dec 22, 2021 11:18am
Oncotelic Announces that ORF8 Mutations are Driving the...
Oncotelic Announces that ORF8 Mutations are Driving the Evolution of the Delta and the Omicron Variants: https://www.globenewswire.com/news-release/2021/12/22/2356662/0/en/ONCOTELIC-ANNOUNCES
...more
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Dec 14, 2021 12:06pm
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 | News Direct
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Dec 08, 2021 7:36pm
Mesothelioma Clinical Trial to Involve Drug Studied forCOVID
Mesothelioma Clinical Trial to Involve Drug Studied for COVID-19: https://www.asbestos.com/news/2021/12/07/mesothelioma-trial-covid-19-drug/
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Dec 07, 2021 6:43pm
Oncotelic 2021 Q3 Report, Litchfield reiterates $4 12 month
Oncotelic 2021 Q3 Report, Litchfield reiterates $4 12 month PT: https://www.otcmarkets.com/financialReportViewer?id=314866
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Dec 03, 2021 7:25pm
Biotech Growth Stocks Set to Benefit from Rising Volatility
https://www.benzinga.com/pressreleases/21/12/ab24422302/biotech-growth-stocks-set-to-benefit-from-rising-volatility-regn-otlc-amgn-ilmn-lly-gild-mrk
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Nov 29, 2021 6:27pm
New Oncotelic Therapeutics Inc (OTLC) Stock Analysis
https://www.youtube.com/watch?v=x7b7ZXxAeiA
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Nov 22, 2021 7:54pm
Oncotelic Therapeutics Inc (OTLC) stock news and analysis
https://www.youtube.com/watch?v=M-4sS-P0OD0
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Nov 16, 2021 9:25am
$OTLC reporting successful combination of its TGF-beta drug
https://oncotelic.irpass.com/Oncotelic-Announces-Successful-Completion-of-the-Safety-Evaluation-of-a-TGF-946--Inhibitor--OT-101--and-IL-2--Aldesleukin--in-Phase-1-Combination-Trial-in-Solid-Tumor
...more
(0)
•••
DepartedSe7en
X
Post by
DepartedSe7en
on Oct 22, 2021 8:28pm
ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS
ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY: https://oncotelic.irpass.com/ONCOTELIC-ANNOUNCES-UPDATE-ON-THE-OT-101-CLINICAL-PROGRAMS-INCLUDING-C001-COVID
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
MindBio Develops Fatigue Prediction Model using Speech Analytics and AI
AI Beyond the Data Center: The Rise of Computing Everywhere
Podcasts